Concentra Group Holdings Parent (CON) Wells Fargo 21st Annual Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Wells Fargo 21st Annual Healthcare Conference summary
9 Sep, 2026Leadership transition and succession planning
Recent leadership changes were part of a long-term, well-received succession plan, with experienced internal candidates stepping into CEO and CFO roles effective November 1st.
Outgoing CEO will transition to Executive Chairman, while the current Chairman will become a director.
Succession planning extends to other key leaders, ensuring continuity and depth in management.
Business performance and market trends
Strong start to the year with visit growth in both workers' comp and employer services, especially in manufacturing and construction sectors.
Employer services growth is stable at 1%-2%, while workers' comp is outperforming long-term trends.
Blue collar job growth, particularly in healthcare, manufacturing, and construction, is driving volume.
Real-time data from 55,000 daily patients and 250,000 employers provides valuable market insights.
Financial guidance and margin performance
Guidance has been raised multiple times this year, reflecting strong Q1 and Q2 results and continued outperformance.
Margin improvement driven by center-level efficiencies and cost control, with a 240 basis point improvement over Q2 of the prior year.
Margin expansion expected to continue, with a projected 100 basis point increase over prior years.
Latest events from Concentra Group Holdings Parent
- Q2 2026 delivered double-digit revenue growth, margin expansion, and raised full-year guidance.CON
Q2 2026 - Q3 2024 revenue up 3.3% YoY, with stable margins and ongoing expansion across the U.S.CON
Investor presentation - Industry leader with $2.16bn revenue, strong margins, and robust growth across diversified channels.CON
Investor presentation - Acquisition doubles onsite clinic size, creating the top U.S. occupational health provider.CON
Investor presentation - Q1 2026 saw 13.7% revenue growth, margin gains, and raised full-year guidance.CON
Q1 2026 - Director elections, executive pay, and auditor ratification headline a governance-focused proxy.CON
Proxy Filing - Strong 2025 growth, high satisfaction, and disciplined expansion drive robust outlook.CON
44th Annual J.P. Morgan Healthcare Conference - Nova acquisition, strong 2024 results, and 2025 double-digit growth outlook drive expansion.CON
Q4 2024 - Q1 revenue and EBITDA rose 7.1% and 6.8%, with guidance raised and major acquisitions completed.CON
Q1 2025